Gluconorm-G 4 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 4 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which helps reduce blood glucose levels without causing significant hypoglycemia. The combination provides complementary mechanisms of action, making it effective for patients inadequately controlled on monotherapy. Gluconorm-G 4 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise. It is contraindicated in patients with severe renal or hepatic impairment, diabetic ketoacidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which often subside with continued use. Hypoglycemia risk is primarily related to glimepiride and necessitates patient education on recognizing symptoms. Regular monitoring of blood glucose, renal function, and liver enzymes is advised during therapy. This combination offers an effective and convenient option for optimizing glycemic control in type 2 diabetes patients.